Congenital disorders
Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Paul Gougis
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Department of Medical Oncology, Pitié-Salpêtrière Hospital, Paris, France, Assistance Publique-Hôpitaux de Paris, Paris, France.
Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Clinical Investigation Center (CIC-1901), Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France.
Beatriz Grandal
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Floriane Jochum
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Department of Gynecology, Strasbourg University Hospital, Strasbourg, France.
Kevin Bihan
Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Clinical Investigation Center (CIC-1901), Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France.
Florence Coussy
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
Solenn Barraud
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Bernard Asselain
Department of Statistics, Association de Recherche sur les Cancers dont Gynécologiques-Groupe d’Investigateurs National des Etudes des Cancers Ovariens et du sein (ARCAGY-GINECO), Paris, France.
Elise Dumas
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Clara Sebbag
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
Judicael Hotton
Department of Surgical Oncology, Institut Godinot, Reims, France.
Emmanuel Spaggiari
Department of Obstetrics and Maternal-Fetal Medicine, Assistance Publique-Hôpitaux de Paris, Necker Enfants-Malades Hospital, Paris, France.
Jean-Yves Pierga
Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
Raphaëlle Savarino
Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
Enora Laas
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université Paris Cité, Paris, France.
Jean-Philippe Spano
Department of Medical Oncology, Pitié-Salpêtrière Hospital, Paris, France, Assistance Publique-Hôpitaux de Paris, Paris, France.
Institut National de la Santé et de la Recherche Médicale, UMRS 1136, Paris, France.
Fabien Reyal
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Department of Surgical Oncology, Institut Godinot, Reims, France.
Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université Paris Cité, Paris, France.
Anne-Sophie Hamy
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Santé et de la Recherche Médicale, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
